8-K: ORIC Pharmaceuticals Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Updates

ORIC Pharmaceuticals reports financial results for Q4 and full year 2024, highlighting clinical trial progress, strategic collaborations, and a cash runway into late 2026.

Summary

• ORIC Pharmaceuticals announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company reported encouraging early safety and efficacy data for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC.
• ORIC entered into a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations.
• ORIC expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in the second half of 2025 and early 2026.
• The company's cash and investments totaled $256 million as of December 31, 2024, which is expected to fund the operating plan into late 2026.
• Research and development expenses were $32.0 million for the three months ended December 31, 2024, and $114.1 million for the year ended December 31, 2024.
• General and administrative expenses were $7.6 million for the three months ended December 31, 2024, and $28.8 million for the year ended December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the clinical progress, strategic partnerships, and sufficient cash runway, offset by the net losses and increased expenses typical of a clinical-stage company.

Positives

• ORIC has a strong cash position of $256 million, expected to fund operations into late 2026.
• The company has established strategic partnerships with major pharmaceutical companies like Johnson & Johnson and Bayer.
• ORIC is advancing multiple clinical programs, including ORIC-114 and ORIC-944, with anticipated data readouts and potential registrational trials.
• The leadership team was expanded with the appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs.
• ORIC-944 demonstrated a clinical half-life of ~20 hours, robust target engagement, and a generally well-tolerated safety profile in initial Phase 1b single agent data.

Negatives

• The company reported a net loss of $36.3 million for the three months ended December 31, 2024, and $127.8 million for the year ended December 31, 2024.
• Research and development expenses increased to $32.0 million for the three months ended December 31, 2024, and $114.1 million for the year ended December 31, 2024.
• General and administrative expenses increased to $7.6 million for the three months ended December 31, 2024, and $28.8 million for the year ended December 31, 2024.

Risks

• The company's forward-looking statements are subject to numerous risks and uncertainties, including those related to drug development, clinical trials, regulatory approvals, and market competition.
• ORIC relies on third parties for manufacturing and research, which could pose risks to its operations.
• The company's ability to raise additional funding is uncertain.
• Clinical outcomes may materially change as patient enrollment continues or more patient data become available.

Future Outlook

ORIC anticipates multiple data readouts in the next 18 months and is working towards potential registration studies for ORIC-114 in the latter half of 2025 and for ORIC-944 in early 2026.

Management Comments

• '2024 was a year of significant advancements across several areas,' stated Jacob M. Chacko, M.D., president and chief executive officer.
• He highlighted key achievements including initiation of multiple cohorts for ORIC-114 and ORIC-944, strategic partnerships, expanded leadership, and secured financing.

Industry Context

ORIC's focus on overcoming resistance in cancer aligns with the broader industry trend towards precision medicine and targeted therapies. The collaborations with Johnson & Johnson and Bayer indicate a validation of ORIC's approach and potential for its drug candidates in competitive oncology markets.

Comparison to Industry Standards

• ORIC's collaboration with Johnson & Johnson to evaluate ORIC-114 in combination with amivantamab mirrors similar industry partnerships focused on combining EGFR inhibitors with other targeted therapies to improve outcomes in NSCLC.
• The development of ORIC-944 as a PRC2 inhibitor places ORIC in competition with other companies developing epigenetic therapies for cancer, such as Constellation Pharmaceuticals (acquired by MorphoSys) and Epizyme (acquired by Ipsen).
• ORIC's reported cash runway into late 2026 is a key metric for investors, as it provides visibility into the company's ability to fund its clinical programs and achieve key milestones; this is comparable to other clinical-stage biotech companies that prioritize maintaining a sufficient cash balance to support ongoing research and development activities.

Stakeholder Impact

• Shareholders: The announcement provides updates on clinical progress and financial stability, which can influence investor confidence.
• Employees: The company's progress and financial health can impact employee morale and job security.
• Patients: The development of new cancer treatments has the potential to improve patient outcomes.
• Partners: The collaborations with Johnson & Johnson and Bayer impact the development and commercialization strategies for ORIC's drug candidates.

Next Steps

• ORIC anticipates multiple data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months.
• The company is working towards potential initiation of registrational trials for ORIC-114 in the second half of 2025 and for ORIC-944 in early 2026.

Key Dates